For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenues | - | 0 | - | - |
| General and administrative expenses | 904,346 | 1,049,903 | 1,490,796 | 1,291,135 |
| Research and development expenses | 412,639 | 496,197 | 314,404 | 811,858.5 |
| Total operating costs | 1,316,985 | 1,546,100 | 1,805,200 | 2,102,993.5 |
| Interest income | 15,697 | - | - | - |
| Unrealized gain on short-term investments | 176,056 | - | - | - |
| Other income/(expense) | - | -107 | - | - |
| Other expense | 12,441 | - | - | - |
| Interest income | - | 8,495 | -21,421 | -44,260 |
| Other income, expense, net | 179,312 | - | - | - |
| Net loss | -1,137,673 | -1,537,712 | -1,783,779 | -2,058,733.5 |
| Deemed dividend | 21,556,821 | - | - | - |
| Net loss attributable to common shareholders | -22,694,494 | - | - | - |
| Basic loss per share | -1.18 | -0.09 | -0.11 | -0.13 |
| Diluted loss per share | -1.18 | -0.09 | -0.11 | -0.13 |
| Weighted average common stock shares outstanding - basic | 19,274,947 | 16,986,488 | 16,645,119 | -7,204,325.5 |
| Weighted average common stock shares outstanding - diluted | 19,274,947 | 16,986,488 | 16,645,119 | -7,204,325.5 |
MIRA PHARMACEUTICALS, INC. (MIRA)
MIRA PHARMACEUTICALS, INC. (MIRA)